Previous studies using GIP immunoneutralization, GIPR-knockout mice, and GIPR antagonists reported that inhibition of GIP signaling ameliorates HFD-induced obesity and insulin resistance (Miyawaki et al. 2002, McClean et al. 2008, Boylan et al. 2015). Here, GIPR is linked to obesity due to melanocortin 4 receptor deficiency.